Welcome to our dedicated page for Artelo Biosciences SEC filings (Ticker: ARTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Artelo Biosciences, Inc. (NASDAQ: ARTL) SEC filings page on Stock Titan provides structured access to the company’s U.S. Securities and Exchange Commission disclosures, with AI-powered tools to help interpret complex documents. As a clinical-stage biopharmaceutical company focused on lipid-signaling pathways and the endocannabinoid system, Artelo uses its SEC filings to report on clinical development, capital formation, governance changes, and listing status.
Here you can review Form 10-K annual reports and Form 10-Q quarterly reports (when filed) for detailed discussions of Artelo’s pipeline, including programs such as ART27.13 for cancer anorexia-cachexia syndrome, ART26.12 as a FABP5 inhibitor for chemotherapy-induced peripheral neuropathy, and ART12.11, its CBD-TMP cocrystal composition. These reports typically describe risk factors, research and development priorities, intellectual property, and liquidity and capital resources.
Form 8-K current reports are particularly important for ARTL, as they capture material events such as underwritten public offerings, private placements of convertible notes and warrants, cooperation agreements with shareholders, amendments to bylaws and articles of incorporation, executive appointments, and Nasdaq listing notifications. For example, an 8-K dated November 25, 2025 discloses a Nasdaq delist determination letter related to stockholders’ equity requirements and the company’s intention to appeal.
Investors can also use this page to access registration statements such as Form S-1 and Form S-3, which describe the terms of securities offerings, resale registrations for warrants and convertible notes, and related risk disclosures. Where available, Section 16 filings (Forms 3, 4, and 5) provide insight into insider ownership and transactions involving directors and officers.
Stock Titan’s platform enhances these filings with AI-generated summaries that highlight key terms, financial and capital structure changes, and program-related disclosures, helping users quickly understand how each document relates to Artelo’s clinical pipeline, governance, and Nasdaq listing status.
Daniel S. Farb reported on Schedule 13D/A that he directly owns 153,003 shares of Artelo Biosciences, representing approximately 7.7% of outstanding common stock based on an outstanding share count that includes 1,555,493 shares reported September 16, 2025 and 441,210 shares issued in an underwritten offering on October 1, 2025. Farb paid approximately $850,036 in personal funds for the 153,003 shares and also holds 11,299 warrants exercisable at $10.00 per share that expire in June 2030. Those $10 warrants are subject to a beneficial ownership limitation currently set at 4.99%, so Farb cannot exercise the warrants to increase his stake above that limit absent notice to the issuer. Farb also confirmed delivery of the remaining 3 shares underlying previously held $5.82 warrants and no longer holds those warrants.
ArteLo Biosciences, Inc. (ARTL) is offering an aggregate of 454,545 shares of common stock and associated Pre-funded Warrants. The Pre-funded Warrants have an exercise price of $0.001 per share and are immediately exercisable upon issuance until exercised in full. The prospectus supplement also notes Ordinary Shares that will be issuable upon exercise of those Pre-funded Warrants. Separately, the filing includes a brief scientific description that the CB1 receptor is distributed in brain regions tied to motor control, emotion, motivated behavior and energy homeostasis while the CB2 receptor is mainly expressed in the immune system and upregulated in response to tissue stress or damage.
Artelo Biosciences is launching a primary offering of common stock and pre-funded warrants under its existing $75 million shelf registration to raise cash for operations and drug development. The pre-funded warrants carry a nominal $0.001 exercise price and are structured to let larger investors participate without breaching 4.99% or 9.99% ownership caps. Artelo plans to use the proceeds to advance its cannabinoid‑based and lipid‑signaling product candidates through preclinical and clinical work, and for working capital and general corporate purposes.
The company is an early‑stage biotech with no mature products, recurring losses, and substantial doubt about its ability to continue as a going concern. It faces Nasdaq listing risk due to low stockholders’ equity and has recently undertaken highly dilutive financings and complex instruments, including prior private placements and a required purchase of Solana cryptocurrency, whose volatility could further strain liquidity.
The company filed a prospectus supplement under Rule 424(b)(5) to update its at-the-market common stock offering program with R.F. Lafferty & Co., Inc. The supplement reduces the maximum aggregate gross sales price of common stock that may be offered under the sales agreement from this point forward to $0, effectively suspending further sales under the existing ATM prospectus. The company previously registered up to $6,500,000 of common stock for this program, which was reduced to $3,451,527 on September 4, 2025, and all $451,527 of common stock that was available for sale under the amended ATM prospectus has now been sold. As of September 29, 2025, the aggregate market value of outstanding common stock held by non-affiliates was $18,399,248, based on 1,555,493 shares outstanding and a Nasdaq closing price of $11.86 on July 31, 2025.
Daniel S. Farb filed a Schedule 13D disclosing a 9.8% direct stake in Artelo Biosciences, Inc. (symbol ATLEW), owning 153,000 shares purchased with personal funds for approximately $850,019. Farb also acquired warrants under a June 2025 Securities Purchase Agreement: 11,299 $10 warrants and 22,598 $5.82 warrants. He exercised all $5.82 warrants on July 23, 2025, and received 22,595 shares; the issuer declined delivery of 3 shares and intends to pay $17.46 for those undelivered shares. Farb delivered a director nomination letter naming himself and Scott D. Pomfret and entered a Joint Filing and Solicitation Agreement with Pomfret; Pomfret granted Farb a power of attorney to assist with the proxy solicitation. The registered resale of the SPA securities was filed on Form S-1.
Artelo Biosciences, Inc. amended its bylaws to change several shareholder governance provisions. The amendments modify the required notice period for Board special meetings, eliminate the right of stockholders to take action without a meeting, and state that the Company will be treated as an "issuing corporation" under Nevada statutes regardless of its number of record stockholders or whether it does business in Nevada.
The bylaws also set the record date for determining shareholders entitled to notice, to vote, or to receive dividends or distributions at not more than 60 days prior to the relevant action. These are procedural and corporate governance changes reflected in the filing.
Artelo Biosciences, Inc. completed an underwritten equity offering to raise approximately $3,000,000 in gross proceeds. The deal included 640,924 shares of common stock at $4.40 per share and pre-funded warrants to purchase up to 40,894 shares at an exercise price of $0.001 per share, sold at $4.399 per warrant.
The company granted the underwriter a 45-day option to buy up to 102,272 additional shares. Artelo plans to use the net proceeds to advance its product candidates through preclinical and clinical development, fund manufacturing and research, support capital expenditures, and provide working capital for general corporate purposes.
Directors and executive officers agreed to 30-day lock-up restrictions, and the company agreed not to issue additional equity or equity-linked securities for 30 days from closing without the underwriter’s consent. The underwriter also received a right of first refusal for the company’s future financings through December 31, 2025.
Artelo Biosciences' prospectus supplement describes terms for issuing debt securities, warrants and units and the broad rights, remedies and amendment limits under the indenture. It discloses that the company currently receives UK R&D tax credits for clinical trials but expects such credits to be unavailable for expenditures outside the UK with effect from April 2024. The filing states the company will need additional financing to pursue its business objectives and acknowledges failure to obtain financing could materially impair operations. Detailed provisions cover designation, pricing, interest, currency, redemption, default events and amendment/consent thresholds for any series of securities.
Artelo Biosciences (ARTL) disclosure describes terms for offering debt securities, warrants and units under an indenture, including extensive customizable features such as interest rates, denominations, currencies, security, covenants, events of default and amendment limitations. The filing states the company needs additional financing and warns operations could be adversely affected if such financing is unavailable. It notes the company currently receives UK R&D tax credits for clinical trials but those credits are not expected to apply to expenditures outside the UK starting April 2024. The supplement also summarizes trustee remedies, defeasance mechanics, and procedural rights for holders relating to defaults and amendments.
Artelo Biosciences is updating its at-the-market offering to cover up to $3,451,527 of common stock under its existing Sales Agreement with R.F. Lafferty & Co., Inc.
This reduces the prior at-the-market capacity from $6,500,000, and the new cap includes approximately $451,526.95 of common stock already sold under the program. The amendment keeps all other terms of the at-the-market facility and the Sales Agreement unchanged.
The company also notes a public float of $22,062,306 as of a recent date, based on 777,881 shares outstanding and a $28.50 Nasdaq closing price on July 10, 2025, and confirms it will not sell more than one-third of this public float in any 12-month period while the float remains below $75,000,000.